



ITCs

## MDi#Psoriasis

A research group of the Andalusian Public Health System, belonging to Virgen Macarena University Hospital (Seville), has developed a decision-making algorithm that allows systematizing and homogenizing the decision-making in complex patients with psoriasis.



### Description

Psoriasis usually presents with a series of associated diseases (comorbidities) that complicate the therapeutic decision making. These comorbidities are related to an increased risk of toxicity related to systemic psoriasis treatments, as well as increased therapeutic resistance. In addition, there are other factors that significantly influence the therapeutic decision (age, reproductive desire, other drugs, etc.), and are therefore taken into account by the clinician when deciding the most appropriate therapeutic option for each patient.

MDi#Psoriasis is a mobile application (iOS, Android) designed to automate therapeutic decision making on patients with moderate-severe psoriasis. It has been developed from 60 variables related to demographic, clinical and therapeutic antecedents of the patient that faced with the 11 currently available therapeutic options generate more than 600 individualized scenarios of patients with psoriasis.

Thus, MDi#Psoriasis allows to systematize and homogenize the clinical decision making in complex patients, reducing the therapeutic variability and adjusting the decisions in each scenario according to the available scientific evidence. Currently the clinician does not have algorithms that facilitate decision making in complex scenarios characterized by the presence of comorbidities and other therapeutic antecedents.



### Advantages

- Algorithm based on accepted international therapeutic guides (*European Academy of Dermatology, German Society of Dermatology, American Academy of Dermatology*), consensuses and recommendations of

groups of interest (*National Psoriasis Foundation, Grupo de Psoriasis de la AEDV*) and technical data sheets of included drugs.

- Includes all the therapeutic options currently authorized for the treatment of moderate-severe psoriasis.
- Improves the safety of the patient with moderate-severe psoriasis through a system which allows the verification of contraindications, interactions and therapeutic recommendations.
- Clinical use-oriented to dermatologists and general practitioners regardless of their experience in the treatment of psoriasis.



### Intellectual property

This technology is protected by intellectual property rights.



### Objetivos

We are looking for a partner interested in a license to commercialize this innovative technology.



### Classification

Field: IT – Computing – Biocomputing  
Pathology: Dermatology